{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:46:40Z","timestamp":1792583200277,"version":"4.5.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.modpat.2026.101060","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T06:01:00Z","timestamp":1785996060000},"page":"101060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted Transcriptomic Profiling Identifies Biomarkers and Molecular Features Associated With Immunotherapy Response in Classic Hodgkin Lymphoma"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5952-320X","authenticated-orcid":false,"given":"Leticia","family":"Hamana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario L.","family":"Marques-Piubelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaja","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Kakarala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio I.","family":"Wistuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa M.","family":"Solis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5956-452X","authenticated-orcid":false,"given":"Francisco","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.modpat.2026.101060_bib1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/PPO.0000000000000451","article-title":"Lymphoma classification","volume":"26","author":"de Leval","year":"2020","journal-title":"Cancer J"},{"issue":"1","key":"10.1016\/j.modpat.2026.101060_bib2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.modpat.2026.101060_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3239","article-title":"Classic Hodgkin lymphoma","volume":"42","author":"Kahn","year":"2024","journal-title":"Hematol Oncol"},{"issue":"7","key":"10.1016\/j.modpat.2026.101060_bib4","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.modpat.2026.101060_bib5","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/jcm10051125","article-title":"Hodgkin lymphoma\u2014review on pathogenesis, diagnosis, current and future treatment approaches for adult patients","volume":"10","author":"Momotow","year":"2021","journal-title":"J Clin Med"},{"issue":"20","key":"10.1016\/j.modpat.2026.101060_bib6","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.3390\/jcm10204665","article-title":"Hodgkin lymphoma: a special microenvironment","volume":"10","author":"Opinto","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.modpat.2026.101060_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.15614","article-title":"Diagnosis of Hodgkin lymphoma in the modern era","volume":"184","author":"Wang","year":"2019","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.modpat.2026.101060_bib8","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.3390\/cancers15215217","article-title":"Prognostic markers within the tumour microenvironment in classical Hodgkin lymphoma","volume":"15","author":"Martynchyk","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.modpat.2026.101060_bib9","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3390\/diagnostics12061507","article-title":"Hodgkin lymphoma: biology and differential diagnostic problem","volume":"12","author":"Takahara","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"4","key":"10.1016\/j.modpat.2026.101060_bib10","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.modpat.2026.101060_bib11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.molmed.2024.10.004","article-title":"Advances in Hodgkin lymphoma research","volume":"31","author":"K\u00fcppers","year":"2025","journal-title":"Trends Mol Med"},{"issue":"15","key":"10.1016\/j.modpat.2026.101060_bib12","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2017-09-772632","article-title":"Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.modpat.2026.101060_bib13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5644\/ama2006-124.329","article-title":"Classic Hodgkin lymphoma\u2014old disease, new directions: an update on pathology, molecular features and biological prognostic markers","volume":"50","author":"Perry","year":"2021","journal-title":"Acta Med Acad"},{"issue":"22","key":"10.1016\/j.modpat.2026.101060_bib14","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.modpat.2026.101060_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3390\/cancers10060204","article-title":"The role of immune checkpoint inhibitors in classical Hodgkin lymphoma","volume":"10","author":"Meti","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"23","key":"10.1016\/j.modpat.2026.101060_bib16","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.modpat.2026.101060_bib17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CCO.0000000000000396","article-title":"The genetics of Hodgkin lymphoma: an overview and clinical implications","volume":"29","author":"Borchmann","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.modpat.2026.101060_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221149245","article-title":"Genetic lesions and targeted therapy in Hodgkin lymphoma","volume":"14","author":"Li","year":"2023","journal-title":"Ther Adv Hematol"},{"issue":"27","key":"10.1016\/j.modpat.2026.101060_bib19","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10310","key":"10.1016\/j.modpat.2026.101060_bib20","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","article-title":"Classical Hodgkin lymphoma","volume":"398","author":"Brice","year":"2021","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.modpat.2026.101060_bib21","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101060_bib22","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(20)30357-4","article-title":"The role of PET in first-line treatment of Hodgkin lymphoma","volume":"8","author":"Trotman","year":"2021","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101060_bib23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/j.semnuclmed.2022.10.006","article-title":"PET\/CT in Hodgkin lymphoma: an update","volume":"53","author":"Al-Ibraheem","year":"2023","journal-title":"Semin Nucl Med"},{"issue":"6","key":"10.1016\/j.modpat.2026.101060_bib24","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL Trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol"},{"issue":"25","key":"10.1016\/j.modpat.2026.101060_bib25","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1182\/blood.2020008553","article-title":"Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1","volume":"136","author":"Reinke","year":"2020","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.modpat.2026.101060_bib26","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management","volume":"99","author":"Ansell","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.modpat.2026.101060_bib27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2147\/JBM.S250581","article-title":"Salvage therapy for Hodgkin\u2019s lymphoma: a review of current regimens and outcomes","volume":"11","author":"Castagna","year":"2020","journal-title":"J Blood Med"},{"issue":"1","key":"10.1016\/j.modpat.2026.101060_bib28","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(22)00318-0","article-title":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial","volume":"10","author":"Herrera","year":"2023","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.modpat.2026.101060_bib29","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0002-9440(10)63525-0","article-title":"Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology","volume":"163","author":"Mandell","year":"2003","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101060_bib30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.2024024681","article-title":"Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma","volume":"145","author":"Lee","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.modpat.2026.101060_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70126","article-title":"Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed\/refractory Hodgkin lymphoma","volume":"9","author":"Mei","year":"2025","journal-title":"Hemasphere"},{"issue":"14","key":"10.1016\/j.modpat.2026.101060_bib32","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.modpat.2026.101060_bib33","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"issue":"23","key":"10.1016\/j.modpat.2026.101060_bib34","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.modpat.2026.101060_bib35","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"67","key":"10.1016\/j.modpat.2026.101060_bib36","doi-asserted-by":"crossref","first-page":"111386","DOI":"10.18632\/oncotarget.22799","article-title":"Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets","volume":"8","author":"Mata","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.modpat.2026.101060_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101271","article-title":"Classic Hodgkin lymphoma: pathobiological features that impact emerging therapies","volume":"71","author":"Alibrahim","year":"2025","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.modpat.2026.101060_bib38","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/hon.2542","article-title":"Soluble PD-1 and PD-L1 as potential biomarkers for classical Hodgkin lymphoma","volume":"36","author":"da Silva","year":"2018","journal-title":"Hematol Oncol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101060_bib39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-019-0185-9","article-title":"Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma","volume":"9","author":"Jalali","year":"2019","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.modpat.2026.101060_bib40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.modpat.2026.101060_bib41","doi-asserted-by":"crossref","first-page":"599","DOI":"10.25122\/jml-2023-0019","article-title":"Assessment of tumor microenvironment expression and clinical significance of immune inhibitory molecule CTLA-4, ligand B7-1, and tumor-infiltrating regulatory cells in Hodgkin lymphoma","volume":"16","author":"Verma","year":"2023","journal-title":"J Med Life"},{"issue":"23","key":"10.1016\/j.modpat.2026.101060_bib42","first-page":"2059","article-title":"The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.modpat.2026.101060_bib43","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.seminhematol.2024.05.005","article-title":"Molecular biomarkers in classic Hodgkin lymphoma","volume":"61","author":"Kishida","year":"2024","journal-title":"Semin Hematol"},{"issue":"14","key":"10.1016\/j.modpat.2026.101060_bib44","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.2023022197","article-title":"Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma","volume":"145","author":"Gottschlich","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.modpat.2026.101060_bib45","first-page":"1923","article-title":"PD-1, FOXP3, and CSF-1R expression in patients with Hodgkin lymphoma and their prognostic value","volume":"11","author":"Wang","year":"2018","journal-title":"Int J Clin Exp Pathol"},{"issue":"19","key":"10.1016\/j.modpat.2026.101060_bib46","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.3390\/cancers14194893","article-title":"Histological subtypes drive distinct prognostic immune signatures in classical Hodgkin lymphoma","volume":"14","author":"Lamaison","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.modpat.2026.101060_bib47","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1084\/jem.189.12.1939","article-title":"Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells","volume":"189","author":"Kapp","year":"1999","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.modpat.2026.101060_bib48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1006\/cimm.2001.1828","article-title":"Suppression of an IL-13 autocrine growth loop in a human Hodgkin\/Reed-Sternberg tumor cell line by a novel IL-13 antagonist","volume":"211","author":"Oshima","year":"2001","journal-title":"Cell Immunol"},{"issue":"8","key":"10.1016\/j.modpat.2026.101060_bib49","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ijc.28189","article-title":"Targeting the IL-4\/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs","volume":"133","author":"Natoli","year":"2013","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.modpat.2026.101060_bib50","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000049523","article-title":"Interleukin 13: a growth factor in hodgkin lymphoma","volume":"126","author":"Skinnider","year":"2001","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"10.1016\/j.modpat.2026.101060_bib51","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1080\/10428190290026259","article-title":"The role of interleukin 13 in classical Hodgkin lymphoma","volume":"43","author":"Skinnider","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.modpat.2026.101060_bib52","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41467-025-67539-1","article-title":"Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors","volume":"17","author":"Shanmugam","year":"2025","journal-title":"Nat Commun"},{"issue":"15","key":"10.1016\/j.modpat.2026.101060_bib53","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1182\/bloodadvances.2021006336","article-title":"JAK\/STAT blockade reverses the malignant phenotype of Hodgkin and Reed-Sternberg cells","volume":"7","author":"Fern\u00e1ndez","year":"2023","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.modpat.2026.101060_bib54","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.3390\/cancers17203378","article-title":"Colony-stimulating factor 3 receptor mutations and variants in hematological malignancies","volume":"17","author":"Liongue","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.modpat.2026.101060_bib55","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1182\/bloodadvances.2020003664","article-title":"Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma","volume":"5","author":"Gholiha","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.modpat.2026.101060_bib56","article-title":"IL-6 as an inflammatory marker in Hodgkin lymphoma","volume":"5","author":"Tariq","year":"2022","journal-title":"Pak BioMed J"},{"issue":"5","key":"10.1016\/j.modpat.2026.101060_bib57","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/PAP.0000000000000270","article-title":"A 2020 Vision into Hodgkin lymphoma biology","volume":"27","author":"Hurwitz","year":"2020","journal-title":"Adv Anat Pathol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101060_bib58","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/biomedicines10030579","article-title":"Macrophage infiltration correlates with genomic instability in classic Hodgkin lymphoma","volume":"10","author":"Han\u010di\u0107","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.modpat.2026.101060_bib59","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jped.2022.05.004","article-title":"Increased expression of matrix metalloproteinases 2 and 9 as poor prognosis factor for Hodgkin's lymphoma patients","volume":"99","author":"Silva","year":"2023","journal-title":"J Pediatr (Rio J)"},{"key":"10.1016\/j.modpat.2026.101060_bib60","article-title":"Galectin family members: emerging novel targets for lymphoma therapy?","volume":"12","author":"Shi","year":"2022","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.modpat.2026.101060_bib61","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3390\/biom11101398","article-title":"Immunosuppressive roles of galectin-1 in the tumor microenvironment","volume":"11","author":"Huang","year":"2021","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.modpat.2026.101060_bib62","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1034\/j.1600-0609.2002.02751.x","article-title":"Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin\u2019s lymphoma","volume":"69","author":"Kuittinen","year":"2002","journal-title":"Eur J Haematol"},{"issue":"20","key":"10.1016\/j.modpat.2026.101060_bib63","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.3390\/ijms21207524","article-title":"p38\u03b2 and cancer: the beginning of the road","volume":"21","author":"Roche","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.modpat.2026.101060_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188891","article-title":"S100A8 and S100A9 in cancer","volume":"1878","author":"Chen","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"12","key":"10.1016\/j.modpat.2026.101060_bib65","doi-asserted-by":"crossref","first-page":"23774","DOI":"10.3390\/ijms141223774","article-title":"The dual role of Smad7 in the control of cancer growth and metastasis","volume":"14","author":"Stolfi","year":"2013","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.modpat.2026.101060_bib66","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00109-021-02083-1","article-title":"Expression and function of Smad7 in autoimmune and inflammatory diseases","volume":"99","author":"Hu","year":"2021","journal-title":"J Mol Med (Berl)"},{"issue":"6","key":"10.1016\/j.modpat.2026.101060_bib67","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/10409238.2020.1828260","article-title":"Current perspectives on inhibitory SMAD7 in health and disease","volume":"55","author":"de Ceuninck van Capelle","year":"2020","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101060_bib68","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4143\/crt.2008.40.4.197","article-title":"Altered expression of Smad proteins in T or NK-cell lymphomas","volume":"40","author":"Go","year":"2008","journal-title":"Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.modpat.2026.101060_bib69","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.critrevonc.2013.09.004","article-title":"Circulating tumor cells in Hodgkin\u2019s lymphoma\u2014a review of the spread of HL tumor cells or their putative precursors by lymphatic and hematogenous means, and their prognostic significance","volume":"89","author":"Gharbaran","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.modpat.2026.101060_bib70","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/ijlh.13559","article-title":"Serum calprotectin (S100A8\/A9) levels as a new potential biomarker of treatment response in Hodgkin lymphoma","volume":"43","author":"\u015eumnu","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"10.1016\/j.modpat.2026.101060_bib71","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/path.1900","article-title":"The expression of fibroblast growth factors and their receptors in Hodgkin\u2019s lymphoma","volume":"208","author":"Khnykin","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.modpat.2026.101060_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1012193","article-title":"REG4 promotes the proliferation and anti-apoptosis of cancer","volume":"10","author":"Zheng","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"10.1016\/j.modpat.2026.101060_bib73","first-page":"1921","article-title":"Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells","volume":"30","author":"Zheng","year":"2010","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.modpat.2026.101060_bib74","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"7338","key":"10.1016\/j.modpat.2026.101060_bib75","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.modpat.2026.101060_bib76","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1746-1596-2-10","article-title":"Bob-1 is expressed in classic Hodgkin lymphoma","volume":"2","author":"Abd El All","year":"2007","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.modpat.2026.101060_bib77","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1746-1596-5-19","article-title":"Expression and prognostic significance of Cox-2 and p-53 in Hodgkin lymphomas: a retrospective study","volume":"5","author":"Barisik","year":"2010","journal-title":"Diagn Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2026.101060_bib78","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s40364-024-00676-9","article-title":"From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy","volume":"12","author":"Ahmadi","year":"2024","journal-title":"Biomark Res"},{"issue":"15","key":"10.1016\/j.modpat.2026.101060_bib79","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/blood-2011-09-381905","article-title":"FOXO1 is a tumor suppressor in classical Hodgkin lymphoma","volume":"119","author":"Xie","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.modpat.2026.101060_bib80","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1182\/blood-2014-01-553412","article-title":"FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-\u03baB to promote survival of human B cells","volume":"124","author":"van Keimpema","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.modpat.2026.101060_bib81","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1158\/1078-0432.CCR-06-2581","article-title":"Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma","volume":"13","author":"Drakos","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.modpat.2026.101060_bib82","first-page":"92","article-title":"Inhibitor of differentiation 4 (ID4): from development to cancer","volume":"1855","author":"Patel","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"10.1016\/j.modpat.2026.101060_bib83","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.18632\/aging.100855","article-title":"The PTEN tumor suppressor gene and its role in lymphoma pathogenesis","volume":"7","author":"Wang","year":"2015","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.modpat.2026.101060_bib84","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41598-024-51376-1","article-title":"Immune and stromal transcriptional patterns that influence the outcome of classic Hodgkin lymphoma","volume":"14","author":"Men\u00e9ndez","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.modpat.2026.101060_bib85","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3390\/cancers13040682","article-title":"Genomic landscape of Hodgkin lymphoma","volume":"13","author":"Brune","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.modpat.2026.101060_bib86","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semcancer.2016.05.001","article-title":"NF-\u03baB deregulation in Hodgkin lymphoma","volume":"39","author":"Weniger","year":"2016","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"10.1016\/j.modpat.2026.101060_bib87","first-page":"1511","article-title":"Expanding roles of the E2F-RB-p53 pathway in tumor suppression","volume":"12","author":"Zhou","year":"2023","journal-title":"Biology (Basel)"},{"issue":"35","key":"10.1016\/j.modpat.2026.101060_bib88","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1200\/JCO.23.01867","article-title":"Circulating tumor DNA sequencing for biologic classification and individualized risk stratification in patients with Hodgkin lymphoma","volume":"42","author":"Heger","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.modpat.2026.101060_bib89","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1084\/jem.20031080","article-title":"c-FLIP mediates resistance of Hodgkin\/Reed-Sternberg cells to death receptor-induced apoptosis","volume":"199","author":"Mathas","year":"2004","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.modpat.2026.101060_bib90","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1182\/blood-2005-10-4169","article-title":"Role of transforming growth factor-beta in hematologic malignancies","volume":"107","author":"Dong","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.modpat.2026.101060_bib91","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.humpath.2013.10.024","article-title":"c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma","volume":"45","author":"Leventaki","year":"2014","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1016\/j.modpat.2026.101060_bib92","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/leu.2014.345","article-title":"The IL-15 cytokine system provides growth and survival signals in Hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells","volume":"29","author":"Ullrich","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.modpat.2026.101060_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1141208","article-title":"The role of interleukin-15 in the development and treatment of hematological malignancies","volume":"14","author":"Sindaco","year":"2023","journal-title":"Front Immunol"},{"issue":"23","key":"10.1016\/j.modpat.2026.101060_bib94","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.3390\/cancers16234070","article-title":"Pathobiological features and therapeutic opportunities linked to TNF family member expression in classic Hodgkin lymphoma","volume":"16","author":"Alibrahim","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.modpat.2026.101060_bib95","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.3109\/10428194.2011.594926","article-title":"Heterogeneous expression of Src tyrosine kinases Lyn, Fyn and Syk in classical Hodgkin lymphoma: prognostic implications","volume":"52","author":"Mart\u00edn","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"suppl 7","key":"10.1016\/j.modpat.2026.101060_bib96","article-title":"Abstract CT144: safety and efficacy of HMPL-523 (Syk inhibitor) in patients with relapsed or refractory lymphoma","volume":"84","author":"Strati","year":"2024","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.modpat.2026.101060_bib97","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/ijc.21539","article-title":"Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells","volume":"118","author":"Baus","year":"2006","journal-title":"Int J Cancer"},{"issue":"9","key":"10.1016\/j.modpat.2026.101060_bib98","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1158\/1535-7163.MCT-08-0309","article-title":"A small-molecule compound identified through a cell-based screening inhibits JAK\/STAT pathway signaling in human cancer cells","volume":"7","author":"Kim","year":"2008","journal-title":"Mol Cancer Ther"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226001031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:30:13Z","timestamp":1792582213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395226001031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":98,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0893395226001031"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101060","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Transcriptomic Profiling Identifies Biomarkers and Molecular Features Associated With Immunotherapy Response in Classic Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2026.101060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101060"}}